Compare · ARGX vs ESLA
ARGX vs ESLA
Side-by-side comparison of argenx SE (ARGX) and Estrella Immunopharma Inc. (ESLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ESLA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.38B, about 1274.1x ESLA ($43.5M).
- Over the past year, ARGX is up 65.6% and ESLA is up 22.0% - ARGX leads by 43.6 points.
- ARGX has been more active in the news (4 items in the past 4 weeks vs 1 for ESLA).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ESLA).
- Company
- argenx SE
- Estrella Immunopharma Inc.
- Price
- $892.02+1.59%
- $1.11+3.74%
- Market cap
- $55.38B
- $43.5M
- 1M return
- +14.80%
- -11.90%
- 1Y return
- +65.60%
- +21.98%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest ESLA
- SEC Form DEF 14A filed by Estrella Immunopharma Inc.
- SEC Form 10-Q filed by Estrella Immunopharma Inc.
- SEC Form NT 10-Q filed by Estrella Immunopharma Inc.
- SEC Form SCHEDULE 13G filed by Estrella Immunopharma Inc.
- Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
- Amendment: SEC Form 10-K/A filed by Estrella Immunopharma Inc.
- Chief Financial Officer Xu Jiandong bought $2,594 worth of shares (2,100 units at $1.24), increasing direct ownership by 0.38% to 265,488 units (SEC Form 4)
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
- SEC Form 424B3 filed by Estrella Immunopharma Inc.
- Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®